

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,334
				Filing Date	October 27, 2005
				First Named Inventor	Mikhail I. Papisov
				Art Unit	1626
				Examiner Name	Chu, Yong Liang
Sheet	1	of	2	Attorney Docket Number	0492479-0041 (MGH 2170 US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-12/620855		Papisov et al	
	A2*	US-5,075,222	12-24-1991	Hannum et al.	
	A3*	US-5,582,172	12-10-1996	Papisov et al.	
	A4*	US-5,612,037	03-18-1997	Huebner et al.	
	A5*	US-5,624,803	04-29-1997	Noonberg et al.	
	A6*	US-5,817,343	10-06-1998	Burke	
	A7*	US-5,824,784	10-20-1998	Kinstler et al.	
	A8*	US-6,048,837	04-11-2000	Friedman et al.	
	A9*	US-6,057,431	05-02-2000	Ishihara et al.	
	A10*	US-6,294,170	09-25-2001	Boone et al.	
	A11*	US-20020082362	06-27-2002	Brocchini et al.	
	A12*	US-20050169968	08-04-2005	Elmaleh et al.	
	A13*	US-7,160,924	01-09-2007	Kinstler et al.	
	A14*	US-7,270,808	09-18-2007	Cheng et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP-0280474-A2	08-31-1988	Johnson Matthey Inc		
	B2	EP-0325270-A2	07-26-1989	Green Cross Corp		
	B3	WO-9605309-A2	02-22-1996	Univ Rockefeller et al.		
	B4	WO-9640912-A1	12-19-1996	Amgen Inc		
	B5	WO-98/05363-A2	02-12-1998	Ortho Pharma Corp		
	B6	WO-9930561-A1	06-24-1999	Nexstar Pharmaceuticals Inc		
	B7	WO-99/64595-A1	12-16-1999	Jolla Pharma et al.		
	B8	WO-0078355-A2	12-28-2000	MI Lab et al.		
	B9	WO-0107486-A1	02-01-2001	Polygene Ltd et al.		
	B10	WO-0110468-A2	02-15-2001	Gen Hospital Corp et al.		
	B11	WO-03059988-A2	07-24-2003	Gen Hospital Corp et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bendele et al., Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins, Toxicological Sciences, 42: 152-157 (1997)	
	C2	Bruneel D. et al. "Chemical modification of pullulan: 3. Succinoylation" Polymer, Elsevier Science Publishers B.V, GB, vol. 35, no. 12, 1 June 1994, pp 2656-2658	
4631115v 1		Date Considered	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,334
				Filing Date	October 27, 2005
				First Named Inventor	Mikhail I. Papisov
				Art Unit	1626
				Examiner Name	Chu, Yong Liang
Sheet	2	of	2	Attorney Docket Number	0492479-0041 (MGH 2170 US)

	C3	Cervigni S. et al. "Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation" Angew. Chem. Int. Ed. Engl. 1996, 35, No. 11, pp 1230-1232	
	C4	Conover, C. et al. "Physiological Effect of Polyethylene Glycol Conjugation on Stroma-Free Bovine Hemoglobin in the Conscious Dog After Partial Exchange Transfusion, Artificial Organs, Vol. 21, No. 5, 1997, pp 369-378	
	C5	Duncan, R. Polymer-Drug Conjugates. In: Handbook of Anticancer Drug Development, D. Budman, H. Calvert, and E. Rowinsky (Eds.), Lippincott, Williams & Wilkins Philadelphia (2003) pp 239-260	
	C6	Endo et al. Nature of Linkage and Mode of Action of Methotrexate Conjugated with Antitumor Antibodies: Implications for Future Preparation of Conjugates. Cancer Research 48, 3330-3335, June 15, 1988	
	C7	Feng et al. Synthesis and Evaluation of Water-Soluble Paclitaxel Prodrugs. Bioorganic & Medicinal Chemistry Letters 12 (2002) 3301-3303	
	C8	Gao Q. et al. "Drug-induced DNA repair: X-ray structure of a DNA-ditercalinium complex" Proc. Natl. Acad. Sci. USA Vol. 88, pp 2422-2426, March 1991	
	C9	Hermanson G. Bioconjugate Techniques pp 548-569 (1996)	
	C10	Jordan, Craig V. Tamoxifen: A Most Unlikely Pioneering Medicine. Nature Reviews. Volume 2, March 2003, 205-213	
	C11	Matysiak S. "Acetal Oligonucleotide Conjugates In Antisense Strategy" Nucleosides & Nucleotides, 16(5&6), pp 855-861 (1997)	
	C12	Papisov M.I. et al. "Semisynthetic Hydrophilic Polyals" Biomacromolecules 2005, vol. 6, pp 2659-2670	
	C13	PIERCE, NHS-Esters-Maleimide Crosslinkers, June 27, 2002, pages 1-8	
	C14	Tomlinson et al. Polyacetal-Doxorubicin Conjugates Designed for pH-Dependent Degradation. Bioconjugate Chem. 2003, 14, 1096-1106	
	C15	Zalipsky et al. Attachment of Drugs to Polyethylene Glycols. Eur. Polym. J. Vol. 19, No. 12, pp. 1177-1183, 1983	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

4631115v 1		Date Considered	
---------------	--	--------------------	--